Clinical Trials Browser

Glioma × Nivolumab × 1 year × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT07210632 2026-05-11

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Phase EARLY_PHASE1 Recruiting

Brain Neoplasms, Glioma

NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Completed

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT07031765 2025-12-18

Peds CHAMP1ON

Phase 1 Active not recruiting

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma

NCT03718767 2025-11-24

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Phase 2 Active not recruiting

62 enrolled 17 charts

Glioblastoma, Glioma

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 2 Completed

35 enrolled 9 charts

Glioma, Recurrence

NCT06519682 2025-08-29

A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

Phase NA Recruiting

Glioma